Laurus Labs is currently trading at Rs. 351.00, up by 0.85 points or 0.24 % from its previous closing of Rs. 350.15 on the BSE.
The scrip opened at Rs. 349.95 and has touched a high and low of Rs. 351.65 and Rs. 348.00 respectively. So far 1548 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 365.65 on 21-Dec-2020 and a 52 week low of Rs. 61.90 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 365.00 and Rs. 347.00 respectively. The current market cap of the company is Rs. 18789.13 crore.
The promoters holding in the company stood at 32.12 % while Institutions and Non-Institutions held 27.08 % and 40.79 % respectively.
Laurus Labs’ wholly-owned Subsidiary -- Laurus Synthesis has incorporated a wholly-owned subsidiary under name and style Laurus Ingredients. The said incorporation is for undertaking ingredients business and also for setting up Greenfield projects for new synthesis business. The new entity Laurus Ingredients shall be a step-down subsidiary for Laurus Labs.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |